Advancis Pharmaceutical Co., a Germantown-based company that develops and commercializes anti-infective products, closed its previously announced private placement of common stock and warrants, resulting in $24 million of gross proceeds.
The company plans to use the proceeds to support the regulatory approval process of its Amoxicillin PULSYS product candidate, as well as for working capital purposes, a brief said.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.